|
| DHC | MHC | ZH/RH* | ||||||
| Variables | Overall n (%) | M/C n (%) | D n (%) | Overall n (%) | M/C n (%) | D n (%) | Overall n (%) | M/C n (%) | D n (%) |
| Availability of Basic Materials (Yes) | |||||||||
| Diabetes Protocol | 2 (13.3) | 0 (0.0) | 2 (40.0) | 2 (40.0) | 0 (0.0) | 2 (100.0) | 6 (85.7) | 4 (100.0) | 2 (66.7) |
| ECI** Material | 1 (6.7) | 0 (0.0) | 1 (10.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 1 (14.2) | 1 (25.0) | 0 (00.0) |
| Scale | 14 (93.3) | 9 (90.0) | 5 (100.0) | 5 (100.0) | 3 (100.0) | 2 (100.0) | 7 (100.0) | 4 (100.0) | 3 (100.0) |
| Tape/Ribbon | 13 (86.7) | 9 (90.0) | 4 (80.0) | 4 (80.0) | 2 (66.7) | 2 (100.0) | 7 (100.0) | 4 (100.0) | 3 (100.0) |
| Rod | 11 (73.3) | 7 (70.0) | 4 (80.0) | 5 (100.0) | 3 (100.0) | 2 (100.0) | 7 (100.0) | 4 (100.0) | 3 (100.0) |
| Stethoscope | 14 (93.3) | 10 (100.0) | 4 (80.0) | 5 (100.0) | 3 (100.0) | 2 (100.0) | 7 (100.0) | 4 (100.0) | 3 (100.0) |
| Sphygmomanometer | 12 (80.0) | 9 (90.0) | 3 (60.0) | 5 (100.0) | 3 (100.0) | 2 (100.0) | 7 (100.0) | 4 (100.0) | 3 (100.0) |
| Availability of Baseline Checkups (Yes) | |||||||||
| Blood Sugar Test Strips | 13 (86.7) | 9 (90.0) | 4 (80.0) | - | - | - | - | - | - |
| Blood Acetone Test Strips | 14 (93.3) | 9 (90.0) | 5 (100.0) | - | - | - | - | - | - |
| Glycosuria | 8 (53.3)) | 4 (40.0) | 4 (80.0) | 4 (80.0) | 3 (100.0) | 1 (50.0) | 7 (100.0) | 4 (100.0) | 3 (100.0) |
| Blood Acetone | 3 (20.0) | 2 (20.0) | 1 (20.0) | 2 (40.0) | 2 (66.7) | 0 (0.0) | 6 (85.7) | 3 (75.0) | 3 (100.0) |
| Availability of Supplementary Basic Records (Yes) | |||||||||
| Glycemia | - | - | - | 4 (80.0) | 3 (100.0) | 1 (50.0) | 7 (100.0) | 4 (100.0) | 3 (100.0) |
| Creatininemia | - | - | - | 3 (60.0) | 2 (66.7) | 1 (50.0) | 7 (100.0) | 4 (100.0) | 3 (100.0) |
| Glycated Haemoglobin | - | - | - | 2 (40.0) | 1(33.3) | 1 (50.0) | 1 (14.3) | 1 (25.0) | 0 (0.0) |
| Availability of Additional Hospital Records (Yes) | |||||||||
| Proteinuria/24 h | - | - | - |
|
|
| 4 (57.1) | 2 (50.0) | 2 (66.7) |
| Visual Acuity | - | - | - |
|
|
| 6 (85.7) | 3 (75.0) | 3 (100.0) |
| Ocular Fundus | - | - | - |
|
|
| 5 (71.4) | 2 (50.0) | 3 (100.0) |
| Availability of Essential Drugs I | |||||||||
| Glucose Serum | 8 (53.3) | 4 (40.0) | 4 (80.0) | 5 (100.0) | 3 (100.0) | 2 (100.0) | 7 (100.0) | 4 (100.0) | 3 (100.0) |
| Availability of Essential Drugs II and Oxygen Device (Yes) | |||||||||
| Glibenclamide | - | - | - | 4 (80.0) | 3 (100.0) | 1 (50.0) | 3 (42.9) | 1 (25.0) | 2 (66.7) |
| Availability of Essential Drugs III (Yes) | |||||||||
| Metformine | - | - | - | - | - | - | - | - | - |
| Delayed Insulin | - | - | - | - | - | - | 5 (71.4) | 2 (50.0) | 3 (100.0) |
| Short-Acting Insulin | - | - | - | - | - | - | 3 (42.9) | 1 (25.0) | 2 (66.7) |